Metformin - pathogenetic drug of first-line in the treatment of type 2 diabetes
- Authors: Zilov AV1, Zilov AV1
-
Affiliations:
- Issue: No 3 (2009)
- Pages: 38-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/276273
- ID: 276273
Cite item
Full Text
Abstract
We consider the peculiarities of pathogenesis and clinical manifestation of type 2 diabetes mellitus (type 2 diabetes); it is emphasized that type 2 diabetes is part of the metabolic syndrome and it has a typical high risk of atherosclerotic disease of coronary and cerebral vessels. Due to cardio-and angioprotective actions of metformin, we provide the use of this drug in the first-line pharmacotherapy of type 2 diabetes. It is noted that in the major clinical recommendations metformin is considered as the first step in the pharmacotherapy of type 2 diabetes in patients with overweight and obesity.
References
- UK Prospective Diabetes study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in T2 DM (UKPDS 33). Lancet 1998;352:837-53.
- UK Prospective Diabetes study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with T2 DM (UKPDS 34). Lancet 1998;352:854-65.
- Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002;323:3-10.
- Mamputu JC, Wiernsperger NF, Reiner G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003;29:6S71-6S76.
- Hanssson GK. Inflammation and immune response to atherosclerosis. Curr Atheroscler Rep 1999;1:150-55.
- Beekhuizen H, van Furth R. Monocyte adherence to human vascular endothelium. J Leukoc Biol 1993;54:363-78.
- Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab 2003;29:6S77-6S87.
- Esposito K, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes care 2003;26:1647-48.
- Valensi P, et al. The effects of metformin on the capillary permeability to albumin in women patients with cyclic aedema. Angiology 1995;46:401-08.
- Kiesewetter H, et al. Rheological effect of metformin on the blood of patients with dietetically controlled T2 DM. Clin Hemorheol 1987;7:781-91.
- Jansson PAE, et al. The effect of metformin on adipose tissue metabolism and periferal blood flow in subjects with NIDDM. Diabetes Care 1996;19:160-64.
- Kelly JJ, et al. Metabolic and haemodynamic effects of short term metformin administration in normoternsive men. Asm J Hypertension 1995;8:G15
- Sirtory et al. Metformin improves peripheral vascular flow in nonhyperlipidaemic patients with arterial disease. J Cardiovascular Pharmacol 1984;6:914-23.
- Nathan D, et al Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2008;31:1-11.
Supplementary files
